Abstract
The Ras proteins play an important role in cell growth, differentiation, proliferation and survival by regulating diverse signaling pathways. Oncogenic mutant K-Ras is the most frequently mutated class of Ras superfamily that is highly prevalent in many human cancers. Despite intensive efforts to combat various K-Ras-mutant-driven cancers, no effective K-Ras-specific inhibitors have yet been approved for clinical use to date. Since K-Ras proteins must be associated to the plasma membrane for their function, targeting K-Ras plasma membrane localization represents a logical and potentially tractable therapeutic approach. Here, we summarize the recent advances in the development of K-Ras plasma membrane localization inhibitors including natural product-based inhibitors achieved from high throughput screening, fragment-based drug design, virtual screening, and drug repurposing as well as hit-to-lead optimizations.
Original language | English (US) |
---|---|
Pages (from-to) | 2114-2127 |
Number of pages | 14 |
Journal | Current topics in medicinal chemistry |
Volume | 19 |
Issue number | 23 |
DOIs | |
State | Published - 2019 |
Keywords
- Cancer
- Drug discovery
- K-Ras
- K-Ras mutation
- Plasma membrane localization inhibitors
- RAS
ASJC Scopus subject areas
- Drug Discovery